*Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York;
†Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia;
‡Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, California;
§Department of Ophthalmology, Weill-Cornell Medical Center, New York, New York;
¶Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York; and
**Department of Ophthalmology, NYU Langone Health, New York, New York.
Reprint requests: David H. Abramson, MD, FACS, Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; e-mail: [email protected]
Supported in part by grants from the Fund for Ophthalmic Knowledge, Inc, New York, NY and Cancer Center Support Grant (P30 CA008748). The sponsor or funding organization had no role in the design or conduct of this research.
Alkeran and Evomela, the products used in this study, are not labeled for the use under discussion. None of the authors has any conflicting interests to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.retinajournal.com).
